Bharat Biotech is charting out its next leg of growth, for which it is investing Rs 3,000-4,000 crore in building vaccines, doing clinical trials, and having a manufacturing facility and partnerships.
At the same time, Krishna Ella-promoted Biovet is eyeing pole position as a veterinary vaccine player globally. Besides this, Anamay Biotech, led by Krishna Ella’s daughter Jalachari Ella, is focusing on the therapeutics segment, especially wound-care therapies.
“We invested Rs 600-700 crore during the pandemic for the development of Covaxinand other vaccines, and we have recovered more than that,” said Krishna Ella, executive chairman of Bharat Biotech. Business Standard met Ella at Bharat Biotech’sheadquarters in Hyderabad.